Summary Introduction The aim of our study is to verify the role of metalloproteinases in endovascular repair (EVAR) and OPEN surgery treatment for abdominal aortic aneurysm (AAA). Postoperatively, these enzymes could represent an important biomarker to adapt diagnostic tests and further investigations during follow-up. Material and method From 2004 to 2008, 55 patients were considered with AAA. Of these, 33 patients (mean age: 70.1 years), (mean AAA diameter: 5.4 cm) were treated with OPEN surgery (group A) and 22 (mean age: 74.1 years) (mean AAA diameter: 5.1 cm) were treated with EVAR. In 17 of them, there were no signs of endoleak (group B1), while in 5 patients, a presence of endoleak (group B2) was detected. Plasma samples were collected in order to determine MMP-9 activity. Enzyme immunoassay was performed preoperatively at 1, 3, 6 and 12 months. Patients treated conventionally were clinically examined after 1 and 12 months by ultrasound. Patients undergoing EVAR treatment were clinically examined by CT scan after 1, 3, 6 and 12 months. The analysis was done by assessing the interaction over time of the MMP-9 value in B1 and B2 groups. Results The average values observed for MMP-9 were preoperatively and at 1, 3, 6 and 12 months, respectively: in group A 150.8 ng/mL (SD = 30.5), 252.5 ng/mL (SD = 25.2), 315.4 ng/mL (SD = 22.7), 295.3 ng/mL (SD = 26.8), 210.7 ng/mL (SD = 30.2); in group B1 105 ng/mL (SD = 10.8), 125.6 ng/mL (SD = 18), 85.8 ng/mL (SD = 19.9), 95 ng/mL (SD = 20.2), 80.4 ng/mL (SD = 15.6); in group B2 149 ng/mL (29.2), 375.4 ng/mL (SD = 40.2), 215 ng/mL (SD = 35.9), 180 ng/mL (SD = 20.2), 175 ng/mL (SD = 33.4). The MMP-9 level was higher in group B2 compared to group B1 (P = 0.01), suggesting a correlation with the presence of the endoleak. Conclusions This preliminary study shows that MMP-9 may be a biomarker of the presence of endoleak. Other further investigations and larger series are needed to show that metalloproteases could play a role in the follow-up of EVAR treated patients.

ASCOLI MARCHETTI, A., Pratesi, G., DI GIULIO, L., Battistini, M., Massoud, R., Ippoliti, A. (2017). EVAR and OPEN treatment of abdominal aortic aneurysm: What is the role of MMP-9 in the follow-up?. JOURNAL DES MALADIES VASCULAIRES, 42(1), 21-28 [10.1016/j.jdmv.2017.01.004].

EVAR and OPEN treatment of abdominal aortic aneurysm: What is the role of MMP-9 in the follow-up?

ASCOLI MARCHETTI, ANDREA;PRATESI, GIOVANNI;DI GIULIO, LORENZO;BATTISTINI, MARTINA;MASSOUD, RENATO;IPPOLITI, ARNALDO
2017

Abstract

Summary Introduction The aim of our study is to verify the role of metalloproteinases in endovascular repair (EVAR) and OPEN surgery treatment for abdominal aortic aneurysm (AAA). Postoperatively, these enzymes could represent an important biomarker to adapt diagnostic tests and further investigations during follow-up. Material and method From 2004 to 2008, 55 patients were considered with AAA. Of these, 33 patients (mean age: 70.1 years), (mean AAA diameter: 5.4 cm) were treated with OPEN surgery (group A) and 22 (mean age: 74.1 years) (mean AAA diameter: 5.1 cm) were treated with EVAR. In 17 of them, there were no signs of endoleak (group B1), while in 5 patients, a presence of endoleak (group B2) was detected. Plasma samples were collected in order to determine MMP-9 activity. Enzyme immunoassay was performed preoperatively at 1, 3, 6 and 12 months. Patients treated conventionally were clinically examined after 1 and 12 months by ultrasound. Patients undergoing EVAR treatment were clinically examined by CT scan after 1, 3, 6 and 12 months. The analysis was done by assessing the interaction over time of the MMP-9 value in B1 and B2 groups. Results The average values observed for MMP-9 were preoperatively and at 1, 3, 6 and 12 months, respectively: in group A 150.8 ng/mL (SD = 30.5), 252.5 ng/mL (SD = 25.2), 315.4 ng/mL (SD = 22.7), 295.3 ng/mL (SD = 26.8), 210.7 ng/mL (SD = 30.2); in group B1 105 ng/mL (SD = 10.8), 125.6 ng/mL (SD = 18), 85.8 ng/mL (SD = 19.9), 95 ng/mL (SD = 20.2), 80.4 ng/mL (SD = 15.6); in group B2 149 ng/mL (29.2), 375.4 ng/mL (SD = 40.2), 215 ng/mL (SD = 35.9), 180 ng/mL (SD = 20.2), 175 ng/mL (SD = 33.4). The MMP-9 level was higher in group B2 compared to group B1 (P = 0.01), suggesting a correlation with the presence of the endoleak. Conclusions This preliminary study shows that MMP-9 may be a biomarker of the presence of endoleak. Other further investigations and larger series are needed to show that metalloproteases could play a role in the follow-up of EVAR treated patients.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/22 - Chirurgia Vascolare
English
Con Impact Factor ISI
EVAR; Open surgery; AAA; MMP-9; Follow-up; Biomarker
This study was cofinanced by Ministero dell’Istruzione, dell’Università edellaRicercaScientificafunds(MIUR)ex 60% years 2006/2007.
https://doi.org/10.1016/j.jdmv.2017.01.004
ASCOLI MARCHETTI, A., Pratesi, G., DI GIULIO, L., Battistini, M., Massoud, R., Ippoliti, A. (2017). EVAR and OPEN treatment of abdominal aortic aneurysm: What is the role of MMP-9 in the follow-up?. JOURNAL DES MALADIES VASCULAIRES, 42(1), 21-28 [10.1016/j.jdmv.2017.01.004].
ASCOLI MARCHETTI, A; Pratesi, G; DI GIULIO, L; Battistini, M; Massoud, R; Ippoliti, A
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S2542451317300135-main.pdf

accesso aperto

Licenza: Copyright dell'editore
Dimensione 470.9 kB
Formato Adobe PDF
470.9 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/179551
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 5
  • ???jsp.display-item.citation.isi??? ND
social impact